Physician profile
William Barry Lee
NPI 1366406787
$501,326.90
in general payments reported to CMS, 2019-2025
38 companies · $88K in 2025
The $88K reported for 2025 was more than what 99% of Cornea and External Diseases Specialist providers received nationally (typical 2025 total: $477).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $90K · 2020: $47K · 2021: $70K · 2022: $82K · 2023: $80K · 2024: $44K · 2025: $88K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $133K · Travel and Lodging: $25K · Consulting Fee: $21K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $18K · Food and Beverage: $15K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $133,175.00 |
| Travel and Lodging | $24,792.65 |
| Consulting Fee | $21,462.50 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $17,690.00 |
| Food and Beverage | $14,805.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $148,048.72 | 2022-2025 | Miebo, Xiidra, Blink Nutritears |
| Sun Pharmaceutical Industries INC. | $108,692.64 | 2019-2025 | Cequa |
| Glaukos Corporation | $42,917.59 | 2019-2025 | Ce-Marked Kxla System, Kxl System (Not Refurbished), Kxl System |
| Dompe US, INC. | $41,638.14 | 2019-2025 | Oxervate |
| Eyevance Pharmaceuticals LLC | $37,937.38 | 2019-2022 | |
| Oyster Point Pharma, INC. | $31,471.50 | 2022-2025 | Tyrvaya, Ryzumvi |
| Novartis Pharmaceuticals Corporation | $28,914.60 | 2019-2023 | |
| Shire North American Group INC | $17,581.75 | 2019 | |
| Kala Pharmaceuticals, INC. | $12,917.42 | 2019-2022 | |
| Biotissue Holdings INC. | $7,351.23 | 2019-2025 | |
| Eyepoint US, INC. | $7,102.18 | 2019-2020 | |
| Tarsus Pharmaceuticals, INC. | $2,766.98 | 2024-2025 | Xdemvy |
| Ocular Therapeutix, INC. | $2,075.55 | 2019-2020 | |
| Alcon Vision LLC | $1,960.25 | 2019-2025 | Clareon, Unity, Lensx |
| Abbvie INC. | $1,807.05 | 2022-2025 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sight Sciences, INC. | $1,692.98 | 2019-2022 | |
| Carl Zeiss Meditec, INC. | $1,465.00 | 2019-2021 | |
| Johnson & Johnson Surgical Vision, INC. | $1,228.50 | 2019-2025 | Tecnis Iol, Tecnis Simplicity, Veritas Vision System |
| W. L. Gore & Associates, INC. | $650.00 | 2019 | |
| Mallinckrodt Hospital Products INC. | $604.97 | 2020-2024 | Acthar |
| Intuitive Surgical, INC. | $408.63 | 2022 | |
| Harrow Eye, LLC | $389.70 | 2024-2025 | Vevye, Iheezo |
| Allergan, INC. | $362.50 | 2019-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $357.56 | 2019-2021 | |
| Horizon Therapeutics Plc | $223.72 | 2021-2022 | |
| Rxsight INC | $174.53 | 2022-2025 | Rxsight Injector Cartridge, Rxsight Contact Lens, Light Adjustable Lens (Lal) |
| Mallinckrodt Enterprises LLC | $169.77 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $110.28 | 2021 | |
| Carl Zeiss Meditec USA, INC. | $87.92 | 2021 | |
| Genentech USA, INC. | $46.85 | 2021-2025 | Vabysmo |
| Conmed Corporation | $28.05 | 2022 | |
| Dutch Ophthalmic, USA | $25.12 | 2024 | Tissueblue, Eva, Combined Machine |
| Thea Pharma INC. | $24.08 | 2024 | Iyuzeh |
| Akorn, INC. | $23.81 | 2020 | |
| Leadiant Biosciences, INC. | $19.47 | 2025 | Cystaran |
| Amgen INC. | $19.39 | 2024 | Tepezza |
| Biogen, INC. | $17.33 | 2024 | Byooviz |
| Tearlab Corp | $13.76 | 2024 | Scoutpro Osmolarity System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.